Syndax Pharmaceuticals, a Waltham, MA-based developer of cancer therapies, has pulled in $9 million of a planned $16 million in a mixed offering of equity, options, and warrants, according to an SEC filing. Syndax’s past investors include Domain Associates and MPM Capital, which led a $40 million Series A round in 2007. The company launched in 2005 with intellectual property based on the work of Ronald Evans, a professor at San Diego’s Salk Institute for Biological Studies.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
